PT3630177T - Paradigma de tratamento para um tratamento combinado de anticorpo anti cd19 e venetoclax - Google Patents

Paradigma de tratamento para um tratamento combinado de anticorpo anti cd19 e venetoclax

Info

Publication number
PT3630177T
PT3630177T PT187281530T PT18728153T PT3630177T PT 3630177 T PT3630177 T PT 3630177T PT 187281530 T PT187281530 T PT 187281530T PT 18728153 T PT18728153 T PT 18728153T PT 3630177 T PT3630177 T PT 3630177T
Authority
PT
Portugal
Prior art keywords
treatment
venetoclax
antibody
paradigm
combined
Prior art date
Application number
PT187281530T
Other languages
English (en)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PT3630177T publication Critical patent/PT3630177T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT187281530T 2017-05-31 2018-05-30 Paradigma de tratamento para um tratamento combinado de anticorpo anti cd19 e venetoclax PT3630177T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17173712 2017-05-31

Publications (1)

Publication Number Publication Date
PT3630177T true PT3630177T (pt) 2023-11-10

Family

ID=59070416

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187281530T PT3630177T (pt) 2017-05-31 2018-05-30 Paradigma de tratamento para um tratamento combinado de anticorpo anti cd19 e venetoclax

Country Status (27)

Country Link
US (1) US20250186460A1 (pt)
EP (2) EP4268900A3 (pt)
JP (2) JP7399713B2 (pt)
KR (2) KR20200010472A (pt)
CN (1) CN110678201A (pt)
AU (2) AU2018276384B2 (pt)
BR (1) BR112019025034A2 (pt)
CA (1) CA3062400A1 (pt)
CY (1) CY1126559T1 (pt)
DK (1) DK3630177T5 (pt)
ES (1) ES2961940T3 (pt)
FI (1) FI3630177T3 (pt)
HR (1) HRP20231229T1 (pt)
HU (1) HUE063119T2 (pt)
IL (2) IL297461B2 (pt)
LT (1) LT3630177T (pt)
MA (1) MA48751B1 (pt)
MD (1) MD3630177T2 (pt)
MX (2) MX2019014330A (pt)
PL (1) PL3630177T3 (pt)
PT (1) PT3630177T (pt)
RS (1) RS64746B1 (pt)
SG (1) SG11201909715VA (pt)
SI (1) SI3630177T1 (pt)
SM (1) SMT202300338T1 (pt)
WO (1) WO2018220040A1 (pt)
ZA (1) ZA201907369B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392561B (es) 2015-08-21 2025-03-24 Morphosys Ag Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
KR20230028571A (ko) 2016-10-28 2023-02-28 모르포시스 아게 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CA3203587A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
JP5401314B2 (ja) 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP2012518404A (ja) 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Ｃｄ１９に結合するヒト化抗体及びその使用
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR102117202B1 (ko) * 2011-08-16 2020-06-01 모르포시스 아게 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
EP2744515B1 (en) * 2011-08-16 2022-02-09 MorphoSys AG Combination therapy with an anti-cd19 antibody and a nitrogen mustard
MX392561B (es) 2015-08-21 2025-03-24 Morphosys Ag Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
KR20230028571A (ko) * 2016-10-28 2023-02-28 모르포시스 아게 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도

Also Published As

Publication number Publication date
AU2025203436A1 (en) 2025-06-05
IL297461B1 (en) 2024-05-01
AU2018276384A1 (en) 2019-11-07
US20250186460A1 (en) 2025-06-12
MA48751B1 (fr) 2023-11-30
EP4268900A2 (en) 2023-11-01
PL3630177T3 (pl) 2024-04-08
MX2023013228A (es) 2024-04-16
ZA201907369B (en) 2024-04-24
HRP20231229T1 (hr) 2024-02-02
SMT202300338T1 (it) 2023-11-13
LT3630177T (lt) 2023-10-25
IL297461B2 (en) 2024-09-01
ES2961940T3 (es) 2024-03-14
RU2019139552A3 (pt) 2021-09-22
RU2019139552A (ru) 2021-07-01
CY1126559T1 (el) 2026-02-25
KR20240117655A (ko) 2024-08-01
BR112019025034A2 (pt) 2020-06-30
MD3630177T2 (ro) 2024-01-31
JP7399713B2 (ja) 2023-12-18
MA48751A (fr) 2020-04-08
MX2019014330A (es) 2020-02-05
DK3630177T5 (da) 2024-09-02
JP2020521777A (ja) 2020-07-27
CA3062400A1 (en) 2018-12-06
HUE063119T2 (hu) 2024-01-28
JP2024028865A (ja) 2024-03-05
FI3630177T3 (fi) 2023-10-18
AU2018276384B2 (en) 2025-02-13
SI3630177T1 (sl) 2023-12-29
IL270855B (en) 2022-11-01
IL297461A (en) 2022-12-01
EP3630177A1 (en) 2020-04-08
RS64746B1 (sr) 2023-11-30
EP4268900A3 (en) 2024-03-06
DK3630177T3 (da) 2023-10-16
CN110678201A (zh) 2020-01-10
WO2018220040A1 (en) 2018-12-06
EP3630177B1 (en) 2023-08-09
SG11201909715VA (en) 2019-11-28
KR20200010472A (ko) 2020-01-30
IL270855B2 (en) 2023-03-01
IL270855A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
IL271009A (en) Antibodies that specifically bind pd-1 and methods of use
IL269003A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL259924A (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
PL3638698T3 (pl) Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2
PL3458478T3 (pl) Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
HUE061842T2 (hu) A rák kezelésének módszerei anti-PD-1 antitestekkel
EP3556772A4 (en) HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
EP3532100A4 (en) ANTI-PD-L1 ANTIBODIES AND VARIANTS
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
EP3426686C0 (en) Humanized Anti-PACAP Antibodies and Their Uses
PT3484916T (pt) Anticorpos específicos para a tau hiperfosforilada e métodos de utilização dos mesmos
EP3579875C0 (en) ANTI-HUMAN A1 ANTIBODY
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
PT3280440T (pt) Anticorpos anti-c1s humanizados e métodos de utilização destes
SI3475303T1 (sl) Formulacija protitelesa proti CD19
EP3634998C0 (en) ANTI CD3 EPSILON ANTIBODY
EP3480216A4 (en) ANTI-PCSK9 MONOCLONAL ANTIBODIES
PT3532098T (pt) Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações
PL3445785T3 (pl) Humanizowane przeciwciała anty-clever-1 i ich zastosowanie
IL270855A (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
IL287008A (en) Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
PT3463328T (pt) Seladelpar para o tratamento de colangite biliar primária
DK3728328T3 (da) Bispecifik antigenbindende konstruktion